Cryoport, Inc. (CYRX)

NCM – Real vaqt narxi. Valyuta: USD

13.04

-0.13 (-0.99%)

Yopilishda: May 12, 2026, 4:00 PM EDT

05.05.2026

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

04.05.2026

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago.

04.05.2026

Cryoport Reports First Quarter 2026 Financial Results

First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026 Company raises full-year revenue guidance to $192 million - $196 million NASHVILLE, Tenn., May 4, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its first quarter (Q1) of 2026.

20.04.2026

Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026

NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Monday, May 4, 2026 after U.S. markets close.

31.03.2026

Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven

Cryoport receives a buy rating with a $9.1 price target, implying 17% upside by FY 2026. CYRX demonstrated double-digit revenue growth in Q4 2025, led by Life Sciences Services, and improved gross margins to 47.8%. Management targets positive adjusted EBITDA in H2 2026, supported by cost reductions and a strengthened partnership with DHL.

04.03.2026

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

03.03.2026

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.42 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

04.05.2026

Cryoport Reports First Quarter 2026 Financial Results

03.03.2026

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.

11.02.2026

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology.

06.11.2025

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World

Cryoport, Inc. (CYRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cryoport, Inc. (CYRX)

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

Cryoport Reports First Quarter 2026 Financial Results

Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026

Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

Cryoport Reports First Quarter 2026 Financial Results

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

Cryoport Reports First Quarter 2026 Financial Results

Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026

Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

Cryoport Reports First Quarter 2026 Financial Results

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Search stocks

Cryoport, Inc. (CYRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cryoport, Inc. (CYRX)

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

Cryoport Reports First Quarter 2026 Financial Results

Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026

Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

Cryoport Reports First Quarter 2026 Financial Results

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

Cryoport Reports First Quarter 2026 Financial Results

Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026

Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

Cryoport Reports First Quarter 2026 Financial Results

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”